Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 4318416, 11 pages
https://doi.org/10.1155/2017/4318416
Review Article

Genetic Variants in SNCA and the Risk of Sporadic Parkinson’s Disease and Clinical Outcomes: A Review

1Memory Studies Laboratory, Department of Physiology, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil
2Behavioral Neuroscience Laboratory, Department of Pharmacology, Universidade Federal de São Paulo, São Paulo, SP, Brazil

Correspondence should be addressed to Regina Helena Silva; moc.liamg@avlishaniger

Received 13 January 2017; Revised 17 April 2017; Accepted 24 May 2017; Published 11 July 2017

Academic Editor: Hao Deng

Copyright © 2017 Clarissa Loureiro das Chagas Campêlo and Regina Helena Silva. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Fahn, “Description of Parkinson's disease as a clinical syndrome,” Annals of the New York Academy of Sciences, vol. 991, pp. 1–14, 2003. View at Google Scholar · View at Scopus
  2. K. Wirdefeldt, H. Adami, P. Cole, D. Trichopoulos, and J. Mandel, “Epidemiology and etiology of Parkinson's disease: a review of the evidence,” European Journal of Epidemiology, vol. 26, no. 1, supplement, pp. S1–S58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson's disease,” The Lancet Neurology, vol. 5, no. 6, pp. 525–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Satake, Y. Nakabayashi, I. Mizuta et al., “Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease,” Nature Genetics, vol. 41, no. 12, pp. 1303–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Simón-Sánchez, C. Schulte, J. M. Bras, M. Sharma, D. Gibbs Berg Jr. et al., “Genome-wide association study reveals genetic risk underlying Parkinsons disease,” Nature Genetics, vol. 41, pp. 1308–1312, 2009. View at Google Scholar
  6. M. Sharma, J. P. A. Ioannidis, J. O. Aasly et al., “Large-scale replication and heterogeneity in Parkinson disease genetic loci,” Neurology, vol. 79, no. 7, pp. 659–667, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. H. A. Lashuel, C. R. Overk, A. Oueslati, and E. Masliah, “The many faces of α-synuclein: from structure and toxicity to therapeutic target,” Nature Reviews Neuroscience, vol. 14, no. 1, pp. 38–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Bendor, T. Logan, and R. Edwards, “The function of α-synuclein,” Neuron, vol. 79, no. 6, pp. 1044–1066, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. E. Eisbach and T. F. Outeiro, “Alpha-Synuclein and intracellular trafficking: Impact on the spreading of Parkinson's disease pathology,” Journal of Molecular Medicine, vol. 91, no. 6, pp. 693–703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Q. Trojanowski and V. M.-Y. Lee, “Aggregation of neurofilament and α-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia,” Archives of Neurology, vol. 55, no. 2, pp. 151-152, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839-840, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, “α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6469–6473, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Khalaf, B. Fauvet, A. Oueslati et al., “The H50Q mutation enhances αα-synuclein aggregation, secretion, and toxicity,” Journal of Biological Chemistry, vol. 289, no. 32, pp. 21856–21876, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Bozi, D. Papadimitriou, R. Antonellou et al., “Genetic assessment of familial and early-onset Parkinson's disease in a Greek population,” European Journal of Neurology, vol. 21, no. 7, pp. 963–968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Hoffman-Zacharska, D. Koziorowski, O. A. Ross et al., “Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease,” Parkinsonism and Related Disorders, vol. 19, no. 11, pp. 1057–1060, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Ibáñez, A.-M. Bonnet, B. Débarges et al., “Causal relation between α-synuclein gene duplication and familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1169–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Chartier-Harlin, J. Kachergus, C. Roumier et al., “α-synuclein locus duplication as a cause of familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Pals, S. Lincoln, J. Manning et al., “α-Synuclein promoter confers susceptibility to Parkinson's disease,” Annals of Neurology, vol. 56, no. 4, pp. 591–595, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Chiba-Falek and R. L. Nussbaum, “Effect of allelic variation at the NACP-Rep1 repeat upstream of the α-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system,” Human Molecular Genetics, vol. 10, no. 26, pp. 3101–3109, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Chib-Falek, J. W. Touchman, and R. L. Nussbaum, “Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene,” Human Genetics, vol. 113, no. 5, pp. 426–431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. McCarthy, C. Linnertz, L. Saucier et al., “The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant,” Neurogenetics, vol. 12, no. 1, pp. 59–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Sotiriou, G. Gibney, A. D. Baxevanis, and R. L. Nussbaum, “A single nucleotide polymorphism in the 3′UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease,” Neuroscience Letters, vol. 461, no. 2, pp. 196–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Wang, J. M. van der Walt, G. Mayhew et al., “Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein,” The American Journal of Human Genetics, vol. 82, no. 2, pp. 283–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. D. J. Davila-Ortiz de Montellano, M. Rodriguez-Violante, A. Fresan, N. Monroy-Jaramillo, and P. Yescas-Gomez, “Frequency of single nucleotide polymorphisms and alpha-synuclein haplotypes associated with sporadic Parkinsons disease in the Mexican population,” Revue Neurologique, vol. 63, pp. 345–350, 2016. View at Google Scholar
  28. A. A. Davis, K. M. Andruska, B. A. Benitez, B. A. Racette, J. S. Perlmutter, and C. Cruchaga, “Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression,” Neurobiology of Aging, vol. 37, pp. 209.e1–209.e7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. S. García, G. Chavira-Hernández, M. Gallegos-Arreola et al., “The rs3857059 variant of the SNCA gene is associated with Parkinson’s disease in Mexican Mestizos,” Arquivos de Neuro-Psiquiatria, vol. 74, no. 6, pp. 445–449, 2016. View at Publisher · View at Google Scholar
  30. N. Shahmohammadibeni, S. Rahimi-Aliabadi, J. Jamshidi et al., “The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinson’s disease in Iranian population,” Neurological Sciences, vol. 37, no. 5, pp. 731–736, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Wang, Y. Huang, Wei Chen et al., “Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 24, pp. 89–94, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Cheng, L. Wang, N.-N. Li et al., “SNCA rs356182 variant increases risk of sporadic Parkinson's disease in ethnic Chinese,” Journal of the Neurological Sciences, vol. 368, pp. 231–234, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Guella, D. M. Evans, C. Szu-Tu et al., “α-synuclein genetic variability: a biomarker for dementia in Parkinson disease,” Annals of Neurology, vol. 79, no. 6, pp. 991–999, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Chen, W.-Y. Kang, S. Chen et al., “Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease,” Parkinsonism and Related Disorders, vol. 21, no. 6, pp. 610–614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Huang, G. Wang, D. Rowe et al., “SNCA gene, but not MAPT, influences onset age of Parkinson's disease in Chinese and Australians,” BioMed Research International, vol. 2015, Article ID 135674, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Han, Y. Liu, Y. Mi, J. Zhao, D. Liu, and Q. Tian, “Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis,” American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 168, no. 2, pp. 123–134, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. P. Chen, Q.-Q. Wei, R. W. Ou et al., “Genetic variants of snca are associated with susceptibility to Parkinson's disease but not amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population,” PLoS ONE, vol. 10, no. 7, Article ID e0133776, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Gao, R. Liu, E. Zhao et al., “Head injury, potential interaction with genes, and risk for Parkinson's disease,” Parkinsonism and Related Disorders, vol. 21, no. 3, pp. 292–296, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. L. F. Cardo, E. Coto, L. de Mena et al., “Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms,” Neuroscience Letters, vol. 562, pp. 45–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Y. Guo, Y. P. Chen, W. Song et al., “SNCA variants rs2736990 and rs356220 as risk factors for Parkinson's disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population,” Neurobiology of Aging, vol. 35, no. 12, pp. 2882.e1–2882.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Pan, H. Ding, H. Dong et al., “Association of polymorphism in rs2736990 of the -synuclein gene with Parkinson′s disease in a Chinese population,” Neurology India, vol. 61, no. 4, pp. 360–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. I. F. Mata, J. B. Leverenz, D. Weintraub et al., “APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease,” JAMA Neurology, vol. 71, no. 11, pp. 1405–1412, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Markopoulou, J. M. Biernacka, S. M. Armasu et al., “Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?” Parkinsonism and Related Disorders, vol. 20, no. 6, pp. 584–589, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Emelyanov, P. Andoskin, A. Yakimovskii et al., “SNCA, LRRK2, MAPT polymorphisms and Parkinson's disease in Russia,” Parkinsonism and Related Disorders, vol. 19, no. 11, pp. 1064-1065, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Y.-H. Wu-Chou, Y.-T. Chen, T.-H. Yeh et al., “Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort,” Parkinsonism and Related Disorders, vol. 19, no. 2, pp. 251–255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Brockmann, C. Schulte, A.-K. Hauser et al., “SNCA: major genetic modifier of age at onset of Parkinson's disease,” Movement Disorders, vol. 28, no. 9, pp. 1217–1221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. S. J. Chung, S. M. Armasu, K. J. Anderson et al., “Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions,” Parkinsonism and Related Disorders, vol. 19, no. 6, pp. 595–599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Pihlstrøm, G. Axelsson, K. A. Bjørnarå et al., “Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease,” Neurobiology of Aging, vol. 34, no. 6, pp. 1708.e7–1708.e13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. M. G. Heckman, A. I. Soto-Ortolaza, N. N. Diehl et al., “Evaluation of the role of SNCA variants in survival without neurological disease,” PLoS ONE, vol. 7, no. 8, Article ID e42877, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Ritz, S. L. Rhodes, Y. Bordelon, and J. Bronstein, “α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease,” PLoS ONE, vol. 7, no. 5, Article ID e36199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Schmitt, U. Wüllner, J. P. Van Rooyen et al., “Variants in the 3′UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression,” European Journal of Human Genetics, vol. 20, no. 12, pp. 1265–1269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Miyake, K. Tanaka, W. Fukushima et al., “SNCA polymorphisms, smoking, and sporadic Parkinson's disease in Japanese,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 557–561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Pan, H. Dong, H. Ding et al., “SNP rs356219 of the α-synuclein (SNCA) gene is associated with Parkinson's disease in a Chinese Han population,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 632–634, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. L. F. Cardo, E. Coto, L. de Mena et al., “A search for SNCA 3′ UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease,” Journal of Molecular Neuroscience, vol. 47, no. 3, pp. 425–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Gao, M. A. Nalls, M. Shi et al., “An exploratory analysis on gene-environment interactions for Parkinson disease,” Neurobiology of Aging, vol. 33, no. 10, pp. 2528.e1–2528.e6, 2012. View at Publisher · View at Google Scholar
  56. L. Trotta, I. Guella, G. Soldà et al., “SNCA and MAPT genes: independent and joint effects in Parkinson disease in the Italian population,” Parkinsonism and Related Disorders, vol. 18, no. 3, pp. 257–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Hu, B. Tang, J. Guo et al., “Variant in the 30 region of SNCA associated with Parkinson's disease and serum α-synuclein levels,” Journal of Neurology, vol. 259, no. 3, pp. 497–504, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Botta-Orfila, M. Ezquerra, P. Pastor et al., “Age at onset in LRRK2-associated PD is modified by SNCA variants,” Journal of Molecular Neuroscience, vol. 48, no. 1, pp. 245–247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. I. F. Mata, D. Yearout, V. Alvarez et al., “Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease,” Movement Disorders, vol. 26, no. 5, pp. 819–823, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. S. J. Chung, S. M. Armasu, J. M. Biernacka et al., “Common variants in PARK loci and related genes and Parkinson's disease,” Movement Disorders, vol. 26, no. 2, pp. 280–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Elbaz, O. A. Ross, J. P. A. Ioannidis et al., “Independent and joint effects of the MAPT and SNCA genes in Parkinson disease,” Annals of Neurology, vol. 69, no. 5, pp. 778–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Wider, C. Vilariño-Güell, M. G. Heckman et al., “SNCA, MAPT, and GSK3B in Parkinson disease: A gene-gene interaction study,” European Journal of Neurology, vol. 18, no. 6, pp. 876–881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Botta-Orfila, M. Ezquerra, J. Ríos et al., “Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease,” European Journal of Neurology, vol. 18, no. 3, p. e32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. M. Biernacka, S. M. Armasu, J. M. Cunningham, J. Eric Ahlskog, S. J. Chung, and D. M. Maraganore, “Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?” Parkinsonism and Related Disorders, vol. 17, no. 10, pp. 730–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. I. F. Mata, M. Shi, P. Agarwal et al., “SNCA variant associated with Parkinson disease and plasma α-synuclein level,” Archives of Neurology, vol. 67, no. 11, pp. 1350–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Yu, P. Xu, X. He et al., “SNP rs7684318 of the α-synuclein gene is associated with Parkinson's disease in the Han Chinese population,” Brain Research, vol. 1346, pp. 262–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. F.-Y. Hu, W.-B. Hu, L. Liu et al., “Lack of replication of a previously reported association between polymorphism in the 3'UTR of the alpha-synuclein gene and Parkinson's disease in Chinese subjects,” Neuroscience Letters, vol. 479, no. 1, pp. 31–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. N. M. Gatto, S. L. Rhodes, A. D. Manthripragada et al., “Alpha-synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease,” Neuroepidemiology, vol. 35, no. 3, pp. 191–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Rajput, C. Vilariño-Güell, M. L. Rajput et al., “Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population,” Movement Disorders, vol. 24, no. 16, pp. 2411–2414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. G. T. Sutherland, G. M. Halliday, P. A. Silburn et al., “Do polymorphisms in the familial parkinsonism genes contribute to risk for sporadic Parkinson's disease?” Movement Disorders, vol. 24, no. 6, pp. 833–838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Brighina, N. K. Schneider, T. G. Lesnick et al., “α-Synuclein, alcohol use disorders, and Parkinson disease: a case-control study,” Parkinsonism and Related Disorders, vol. 15, no. 6, pp. 430–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. D. M. Kay, S. A. Factor, A. Samii et al., “Genetic association between α-synuclein and idiopathic Parkinson's disease,” American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 147, no. 7, pp. 1222–1230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Myhre, M. Toft, J. Kachergus et al., “Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population,” Acta Neurologica Scandinavica, vol. 118, no. 5, pp. 320–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Verbaan, S. Boesveldt, S. M. van Rooden et al., “Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?” Neurology, vol. 71, no. 23, pp. 1877–1882, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Brighina, R. Frigerio, N. K. Schneider et al., “α-Synuclein, pesticides, and Parkinson disease: a case-control study,” Neurology, vol. 70, no. 16, pp. 1461–1469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. O. A. Ross, D. Gosal, J. T. Stone et al., “Familial genes in sporadic disease: common variants of α-synuclein gene associate with Parkinson's disease,” Mechanisms of Ageing and Development, vol. 128, no. 5-6, pp. 378–382, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Winkler, J. Hagenah, S. Lincoln et al., “α-Synuclein and Parkinson disease susceptibility,” Neurology, vol. 69, no. 18, pp. 1745–1750, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Goris, C. H. Williams-Gray, G. R. Clark et al., “Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease,” Annals of Neurology, vol. 62, no. 2, pp. 145–153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. G. M. Hadjigeorgiou, G. Xiromerisiou, V. Gourbali et al., “Association of α-synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset,” Movement Disorders, vol. 21, no. 4, pp. 534–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. J. C. Mueller, J. Fuchs, A. Hofer et al., “Multiple regions of α-synuclein are associated with Parkinson's disease,” Annals of Neurology, vol. 57, no. 4, pp. 535–541, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. C. E. Mamah, T. G. Lesnick, S. J. Lincoln et al., “Interaction of α-synuclein and tau genotypes in Parkinson's disease,” Annals of Neurology, vol. 57, no. 3, pp. 439–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Spadafora, G. Annesi, A. A. Pasqua et al., “NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy,” Neuroscience Letters, vol. 351, no. 2, pp. 75–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Izumi, H. Morino, M. Oda et al., “Genetic studies in Parkinson's disease with an α-synuclein/NACP gene polymorphism in Japan,” Neuroscience Letters, vol. 300, no. 2, pp. 125–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Fuchs, A. Tichopad, Y. Golub et al., “Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain,” FASEB Journal, vol. 22, no. 5, pp. 1327–1334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. M. A. Nalls, N. Pankratz, C. M. Lill et al., “Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease,” Nature Genetics, vol. 46, no. 9, pp. 989–993, 2014. View at Publisher · View at Google Scholar
  86. C. B. Do, J. Y. Tung, E. Dorfman et al., “Web-based genome-wide association study identifies two novel loci and a substantial genetic component for parkinson's disease,” PLoS Genetics, vol. 7, no. 6, Article ID e1002141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Z. Wang, H. Lei, M. Zheng, Y. Li, Y. Cui, and F. Hao, “Meta-analysis of the association between alzheimer disease and variants in GAB2, PICALM, and SORL1,” Molecular Neurobiology, vol. 53, no. 9, pp. 6501–6510, 2016. View at Publisher · View at Google Scholar · View at Scopus
  88. E. K. Tan, H. K. Kwok, L. C. Tan, W. T. Zhao, K. M. Prakash, W. L. Au et al., “Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus,” Neurology, vol. 75, pp. 508–512, 2010. View at Publisher · View at Google Scholar
  89. S. Lesage and A. Brice, “Parkinson's disease: from monogenic forms to genetic susceptibility factors,” Human Molecular Genetics, vol. 18, no. R1, pp. R48–R59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. J. N. Foo, S. J. Chung, L. C. Tan et al., “Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease,” Movement Disorders, vol. 31, no. 4, pp. 484–487, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. D. M. Maraganore, M. de Andrade, A. Elbaz et al., “Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease,” The Journal of the American Medical Association, vol. 296, no. 6, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. L. L. Venda, S. J. Cragg, V. L. Buchman, and R. Wade-Martins, “α-Synuclein and dopamine at the crossroads of Parkinson's disease,” Trends in Neurosciences, vol. 33, no. 12, pp. 559–568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. J. A. Firestone, T. Smith-Weller, G. Franklin, P. Swanson, W. T. Longstreth Jr., and H. Checkoway, “Pesticides and risk of parkinson disease: a population-based case-control study,” Archives of Neurology, vol. 62, no. 1, pp. 91–95, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. K. M. Semchuk, E. J. Love, and R. G. Lee, “Parkinson's disease and exposure to rural environmental factors: a population based case-control study,” Journal Canadien des Sciences Neurologiques, vol. 18, no. 3, pp. 279–286, 1991. View at Publisher · View at Google Scholar · View at Scopus
  95. M. F. Allam, A. S. Del Castillo, and R. Fernández-Crehuet Navajas, “Parkinson's disease risk factors: genetic, environmental, or both?” Neurological Research, vol. 27, no. 2, pp. 206–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. M. F. Allam, M. J. Campbell, A. Hofman, A. S. Del Castillo, and R. F.-C. Navajas, “Smoking and Parkinson's disease: systematic review of prospective studies,” Movement Disorders, vol. 19, no. 6, pp. 614–621, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. X. Li, W. Li, G. Liu, X. Shen, and Y. Tang, “Association between cigarette smoking and Parkinson's disease: a meta-analysis,” Archives of Gerontology and Geriatrics, vol. 61, no. 3, pp. 510–516, 2015. View at Publisher · View at Google Scholar
  98. J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro, “Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studiess,” Journal of Alzheimer's Disease, vol. 20, supplement 1, pp. S221–S238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. S. S. Bettiol, T. C. Rose, C. J. Hughes, and L. A. Smith, “Alcohol consumption and Parkinson's disease risk: a review of recent findings,” Journal of Parkinson's Disease, vol. 5, no. 3, pp. 425–442, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Riederer, C. Konradi, G. Hebenstreit, and M. Youdim, “Neurochemical perspectives to the function of monoamine oxidase,” Acta Neurologica Scandinavica, vol. 80, pp. 41–45, 1989. View at Publisher · View at Google Scholar
  101. G. S. Shahi and S. M. Moochhala, “Smoking and Parkinson's disease—a new perspective,” Reviews on Environmental Health, vol. 9, no. 3, pp. 123–136, 1991. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Savica, W. A. Rocca, and J. E. Ahlskog, “When does Parkinson disease start?” Archives of Neurology, vol. 67, no. 7, pp. 798–801, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Farrer, J. Kachergus, L. Forno et al., “Comparison of kindreds with Parkinsonism and α-synuclein genomic multiplications,” Annals of Neurology, vol. 55, no. 2, pp. 174–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Linnertz, L. Saucier, D. Ge et al., “Genetic regulation of α-synuclein mRNA expression in various human brain tissues,” PLoS ONE, vol. 4, no. 10, Article ID e7480, 2009. View at Publisher · View at Google Scholar · View at Scopus